drugset
drugset / Trial / NCT04065308

Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma

NCT04065308 ↗

Phase 2 Unknown 33 enrolled Seoul National University Hospital
NaSingle-groupOpen-labelTreatment

Summary

This trial aimed to investigate the therapeutic efficacy of daratumumnab plus chemitherapy in multiple myeloma with plasmacytoma.

Timeline

Start
2019-01-14
Primary completion
2019-12-21
Completion
2021-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Daratumumab Monoclonal antibody 16 mg/kg —
Background Cisplatin Other / unclassified 7 mg/m2 Intravenous
Background Cyclophosphamide Other / unclassified 400 mg/m2 Intravenous
Background Dexamethasone Small molecule 40 mg Intravenous
Background Etoposide Small molecule 40 mg/m2 Intravenous
Background Pegteograstim Protein / enzyme biologic 6 mg Subcutaneous

Indications

plasma cell myeloma plasmacytoma